Physician
Internal Medicine
Dr. Yago L. Nieto, MD
|
|
Give Review
Yago Nieto works in the field of Internal Medicine. Yago Nieto is a published MD. He published 98 publications, including: 'End-stage acute hepatic failure as clinical presentation of liver metastases from breast cancer.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
- Autologous hematopoietic stem Cell transplantation in light chain amyloidosis (AL) with renal involvement.
- Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases.
- Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.
- Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
- Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
- Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet enGraftment after transplantation.
- Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hemato...
- Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem Cell transplantation for relapsed myeloma.
- Progressive multifocal leukoencephalopathy after allogeneic bone marrow transplantation for Acute myeloid leukemia.
- Short-term cardiac toxicity of autologous hematopoietic stem Cell transplant for multiple myeloma.
- Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
- Isolated Renal MucorMycosis in a Transplantation Recipient.
- The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.
- Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor Cell mobilization.
- A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients w...
- Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple Myeloma: Relevance of p53 and its clinical implic...
- Outcomes of adults with Acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT).
- Transplantation for Refractory Germ Cell Tumors: Does it Really Make a Difference?
- Incidence and natural history of pure red Cell aplasia in major ABO-mismatched haematopoietic Cell transplantation.
- Cord-blood enGraftment with ex vivo mesenchymal-cell coculture.
- Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome.
- High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-Cell transplantation in patients with refractory lymphoid malignancies.
- Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with Acute lymphoblastic leukemia.
- Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transpla...
- Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplant.
- Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell...
- Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.
- Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in Lymphoma cell lines.
- Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in Lymphoma cell lines.
- Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced Lymphoma patients: a feasibility...
- Prognostic analysis of pre-transplant peripheral T-Cell levels in patients receiving an autologous hematopoietic progenitor-Cell transplant.
- Idiopathic hyperammonemia following high-dose chemotherapy.
- Primary central nervous system Lymphoma treated with rituximab plus temozolomide in a second line schedule.
- Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast Cancer ...
- Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab.
- Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma.
- Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.
- High-dose chemotherapy in gynecologic malignancies.
- High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast Cancer.
- [High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast Cancer].
- Standard versus high-dose therapy in 10+ breast Cancer.
- Preliminary results. UFT/methotrexate/leucovorin for Breast Ca patients in progression after HDCT/PBPC support.
- Peripheral blood stem Cell harvesting and CD34-positive Cell selection.
- Ifosfamide encephalopathy and methylene-blue: a case report.
- Pharmacokinetics of high-dose chemotherapy.
- Unrelated umbilical cord blood stem Cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem Cell transplant.
- Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic Anemia.
- West Nile virus infection in bone marrow transplant patients.
- Intensive chemotherapy for progressive chronic lymphocytic Leukemia administered early after a nonmyeloablative allograft.
- DNA-binding agents.
- Pharmacodynamics of high-dose chemotherapy.
- Status of high-dose chemotherapy for breast Cancer: a review.
- Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast Cancer.
- Peripheral blood stem cell transplantation in breast Cancer.
- Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation.
- Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast Cancer.
- Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast Cancer patients treated with high-dose chemotherapy and au...
- A predictive model for relapse in high-risk primary breast Cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
- Autologous stem-Cell transplantation for solid tumors in adults.
- High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast Cancer who have relapsed after previous high-dose chemotherapy.
- Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast Cancer with minimal metastatic disease.
- Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem Cell transplant.
- Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast Cancer.
- Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea.
- Acute encephalopathy: a new toxicity associated with high-dose paclitaxel.
- End-stage Acute hepatic failure as clinical presentation of liver metastases from breast cancer.
- Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast Cancer patients with primary resistance to doxorubicin.
- [Parenteral nutrition of patients under intensive chemotherapy: comparative study of two lipid emulsions].
- Failure is not fatal: long-term remission in refractory Acute myeloid leukemia (AML) after graft failure of cord blood stem cells.
- High-dose chemotherapy with autologous stem cell transplant for breast Cancer: what have we learned 25 years later?
- Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin Lymphoma: pre...
- Ex vivo Graft purging and expansion of autologous blood progenitor cell products from patients with Multiple Myeloma.
- Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with Acute myeloid leukemia or myelodysplastic ...
- Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem Cell transplantation in patients with advanced lympho...
- Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem Cell transplantation.
- Prognostic value of nodal ratios in node-positive breast Cancer: a compiled update.
- High-dose chemotherapy for high-risk primary and metastatic breast Cancer: is another look warranted?
- Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-pos...
- Methodology for updating published evidence-based reviews evaluating the role of blood and marrow transplantation in the treatment of selected Diseases: a policy sta...
- Impairment of filgrastim-induced stem Cell mobilization after prior lenalidomide in patients with multiple myeloma.
- Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem Cell transplantation for hematologic malignancies.
- Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
- The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of Acute myelogenous leukemia in adults: an evidence-based review.
- Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenit...
- Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advan...
- Prognostic value of nodal ratios in node-positive breast Cancer.
- Docetaxel administered during pregnancy for inflammatory Breast carcinoma.
- Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-Cell transplantations conditioned with fludarabine and low-dose total...
- The evolution of the evidence-based review: evaluating the science enhances the art of medicine--statement of the Steering Committee for Evidence-Based Reviews of the ...
- Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast Cancer receiving high-dose chemotherapy.
- Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor Cell support, in patients with advance...
- Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast Cancer.
- Stem-Cell transplantation for the treatment of advanced solid tumors.
- Prognostic analysis of early lymphocyte recovery in patients with advanced breast Cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor c...
- Acute renal failure after nonmyeloablative hematopoietic cell transplantation.
- Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast Cancer receiving high-dose chemotherapy and autologous hematop...
Schools
University Navarre
Madrid University Hospital
University Of Colorado
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Breast Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1245243948 | |
| NPPES Provider LastName | NIETO | |
| NPPES Provider FirstName | YAGO | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 366.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1245243948 |
| Last Name Of The Provider | NIETO |
| First Name Of The Provider | YAGO |
| View All |
Similar Doctors
|
|
Dr. Qingguo Tao, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Kaushal K. Gupta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edmundo D. Yrigoyen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anam Khan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rosalyn Adigun, MD |
|
|
Dr. Maria A. Rodriguez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven M. Kornblau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Syed U. Akhtar, MD |
|
|
Dr. Annisa L. Lewis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lajos Pusztai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chitra Balasundaram, MD |
|
|
Dr. Mathews L. George, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin J. Hrgovcic, MD |
|
|
Dr. Shilpan S. Shah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Farhad Ravandi-Kashani, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Raoul Tibes |
|
Dr. Enrique B. Granda Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Nitin Kapur, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ankur Sarkar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adnan Rafiq, MD
This Doctor is OpenDoctor Recommended.
|